[Importance of determining clozapine plasma level in follow-up of schizophrenic patients].
Measures of plasma clozapine were carried out for 15 subjects, for up to 35 months. A positive quadratic relation (r = 0.528, n = 111, p < 0.01) has been established by using different samples at different times from each patient. From 500 mg/day this relation point to forecast an important growth of clozapine plasma concentrations. The analysis of individual data shows a large variability for the individuals and a relative stability in plasma levels for a subject having one posology. The repetition of the dosages attests the compliance. A case of epilepsy, related to an important clozapine level, is presented. So, in practice, even if neither non linear pharmacokinetics, nor genetic polymorphism have been demonstrated, over a posology of 500 mg/day, it seems interesting to proceed a clozapine dosage before increasing the posology and so reduce the comitial seizure risk.
Vailleau
J L
JL
CHS La Chartreuse, service Pharmacie, Dijon.
Jeanny
B
B
Chomard
P
P
Vincent
R
R
D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D003024:Clozapine / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008657:Metabolic Clearance Rate / Q000502:physiology; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy; D012565:Schizophrenic Psychology
D014150:Antipsychotic Agents; D003024:Clozapine
Intérêt de la détermination de la clozapine plasmatique dans le suivi des schizophrènes.